Il beta glucano Nichi BRITE sotto forma di integratore oncologico-nutrizionale ottiene risultati incoraggianti nel tumore pancreatico, come riferito dal Chikamori Hospital, in Giappone

The Nichi BRITE Beta 1,3-1,6 Glucan is produced as an exo-polysaccharide by Aureobasidium Pullulans in a GMP certified facility in Japan and is water soluble. The subjects of Nichi BRITE group in the study were given 250mg Beta glucan as an active ingredient per day for 22 days as an adjuvant, while control group had a placebo instead; both groups were given standard of care treatment. The quantity consumed during the study by each patient is equivalent to four boxes of Nichi BRITE, which comes in a box of 24 sachets, 1.5-gram granule as content with 63 mg active beta glucan as ingredient per sachet. Oral administration was undertaken when possible, and when it was not possible, administration was through feeding gastrostomy or nasogastric tube. No adverse reactions were observed. The efficacy in terms of immune enhancement, cancer biomarker reduction and longer mean survival were reported with Nichi Brite as an adjuvant. (Graphic: Business Wire)

  • The Nichi BRITE Beta 1,3-1,6 Glucan is produced as an exo-polysaccharide by Aureobasidium Pullulans in a GMP certified facility in Japan and is water soluble. The subjects of Nichi BRITE group in the study were given 250mg Beta glucan as an active ingredient per day for 22 days as an adjuvant, while control group had a placebo instead; both groups were given standard of care treatment. The quantity consumed during the study by each patient is equivalent to four boxes of Nichi BRITE, which comes in a box of 24 sachets, 1.5-gram granule as content with 63 mg active beta glucan as ingredient per sachet. Oral administration was undertaken when possible, and when it was not possible, administration was through feeding gastrostomy or nasogastric tube. No adverse reactions were observed. The efficacy in terms of immune enhancement, cancer biomarker reduction and longer mean survival were reported with Nichi Brite as an adjuvant. (Graphic: Business Wire)

TOKYO--()--La somministrazione del beta glucano Nichi BRITE ha portato al miglioramento dei livelli immunitari, a cui ha fatto seguito la riduzione dei biomarcatori del tumore pancreatico e della sua ricorrenza nei pazienti sottoposti a resezione chirurgica di un tumore pancreatico maligno. Sono questi i risultati presentati al congresso ASCO® Breakthrough a Yokohama, in Giappone. I marcatori immunitari IgA e CD209 sono risultati in crescita, mentre CA19-9, il marcatore del tumore pancreatico, e CD44, il marcatore della ricorrenza e della gravità tumorale, risultavano nettamente ridotti nei pazienti che avevano assunto Nichi BRITE rispetto al gruppo di controllo dello studio, effettuato dal team chirurgico gastro-enterologico e di supporto nutrizionale del Chikamori Hospital di Kochi, in Giappone.

Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodità del lettore e devono rinviare al testo in lingua originale, che è l'unico giuridicamente valido.

Contacts

Samuel JK Abraham
info@gncorporation.com

Contacts

Samuel JK Abraham
info@gncorporation.com